October 2007 NVAC Meeting Minutes
The data taken from the 2006 NIS HIM are being used to help allocate VFC budgets to States, for estimating needs for 317 funding, and for research on the underinsured. Improvements made in the 2006 NIS HIM module included State-specific questions to determine whether children were covered by Medicaid or the State Children’s Health Insurance Program (SCHIP) and an improved question about whether respondents’ insurance covered the entire cost of vaccines, excluding costs for copays and office visits. The 2006 NIS HIM also contained national VFC estimates for teenagers 13 to 17 years of age.
Dr. Smith first discussed 2006 NIS HIM data for 19- to 35-month-old children. CDC plans to take these data and study the association between vaccination coverage and being publicly insured, privately insured, underinsured, and uninsured. So far, data have shown that since 2001, the overall percentage of VFC-eligible children has not changed significantly. However, there were significant increases in the percentage of American Indian/Alaskan Native children between 2001 and 2006, and also among the uninsured. Research showed that most children who have private insurance received vaccine doses at private facilities.
The 2006 teen survey included insurance data on approximately 5,468 teens between 13 and 17 years of age. As with the child survey, CDC will continue to research the association between vacation coverage and type of health insurance. The results from the teen survey showed that approximately 34 percent of all 13- to 17-year-old teens were VFC eligible, 23 percent were on Medicaid, 8.8 percent were uninsured, and 20.8 were underinsured at the time of the interview.
The Subcommittee meeting was adjourned.
Subcommittee on Vaccine Safety—Chair: Dr. Andrew Pavia
Subcommittee on Public Communication, Consultation, and Participation—Chair: Dr. Sharon G. Humiston
Attendees: Robert Ball, FDA; Kenneth Bart, NVPO; Karen Broder (by phone), ISO/CDC; Emma English, NVPO; Geoffrey Evans, HRSA/DVIC; Mark Feinberg, NVAC; Meghan Ferris, FDA; Amy Geller, IOM; Bruce G. Gellin, NVPO/NVAC; Sharon G. Humiston, NVAC; David Johnson, sanofi pasteur; Erica Johnson, APCO; Nancy Lavine, CDC; Karen Midthun, CBER/FDA; Christine Nevin-Woods, NVAC; Patrick O’Connor, FDA; Trish Parnell, NVAC; Andrew Pavia, NVAC; Kristin Pope, ISO/CDC; Laura E. Riley, NVAC; Dan Salmon, NVPO; Dixie Snider (by phone), ISO/CDC; John Stander (by phone), ISO/CDC; Melinda Wharton, NCIRD/CDC; Andrea Savoye, notetaker.
Dr. Andrew Pavia began the joint Subcommittee meeting by welcoming attendees and outlining the topics to be discussed during the meeting, including updates on the CDC/ISO research agenda project and the inventory of vaccine safety activities. Dr. Pavia also introduced Dr. Dan Salmon of NVPO, whose responsibilities include coordinating Federal vaccine safety issues and risk communications.
Update on ISO/CDC Research Agenda—Dr. Karen Broder, ISO/CDC
Dr. Karen Broder discussed key themes from the development of the ISO research agenda focusing on phase 1 methods and findings. The overall goal is to develop a comprehensive, scientifically robust research agenda with extensive internal and external input. The research agenda development is a three-phase process: (1) Develop draft agenda, (2) allow NVAC to review agenda and provide feedback, and (3) respond to feedback and update and finalize agenda. The process began in May 2007 and is expected to be completed in 18 months. Upon completion of the research agenda, staff will consider how often it should be revised.